Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

NCT07282041 on ClinicalTrials.gov · last registry update 2025-12-23

An unusually large phase 2/phase 3: 130 participants, more than double the 60 typical for the stage. Due to report 1 December 2030. Sponsors move these dates routinely; any movement since this site started watching is listed below. dulaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2/P3
Drug: dulaglutide
Trulicity
Sponsor: National University of Singapore
Sponsor type: Other
Enrollment: 130
Started: 2025-12-17
Primary completion: 2030-12-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCA

Conditions studied

Intracranial Atherosclerosis · Stroke, Ischemic

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.